These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Targeting of antihapten antibodies to activated T cells via an IL-2-hapten conjugate prolongs cardiac graft survival. Lussow AR; Fanget L; Gao L; Block M; Buelow R; Pouletty P Transplantation; 1996 Dec; 62(12):1703-8. PubMed ID: 8990347 [TBL] [Abstract][Full Text] [Related]
3. Role of antigen-specific T cell help in the generation of in vivo antibody responses. II. Sustained antigen-specific T cell help is required to induce a specific antibody response. Finkelman FD; Villacreses N; Holmes JM J Immunol; 1992 Dec; 149(12):3845-50. PubMed ID: 1281191 [TBL] [Abstract][Full Text] [Related]
4. The immune response against hapten-autologous protein conjugates in the mouse. Rubin B; Wigzell H J Exp Med; 1973 Apr; 137(4):911-31. PubMed ID: 4540327 [TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacokinetics, tissue distribution, and antitumor activity of a folate-hapten conjugate-targeted immunotherapy in hapten-immunized mice. Lu Y; Xu LC; Parker N; Westrick E; Reddy JA; Vetzel M; Low PS; Leamon CP Mol Cancer Ther; 2006 Dec; 5(12):3258-67. PubMed ID: 17172429 [TBL] [Abstract][Full Text] [Related]
6. Targeting BCL1 lymphoma with anti-idiotype antibodies: biodistribution kinetics of directly labeled antibodies and bispecific antibody-targeted bivalent haptens. Manetti C; Rouvier E; Gautherot E; Loucif E; Barbet J; Le Doussal JM Int J Cancer; 1997 Jun; 71(6):1000-9. PubMed ID: 9185704 [TBL] [Abstract][Full Text] [Related]
7. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes. Chapoval AI; Nelson H; Thibault C J Immunol; 1995 Aug; 155(3):1296-303. PubMed ID: 7636196 [TBL] [Abstract][Full Text] [Related]
8. Effects of carrier and hapten array on the production of anti-hapten antibodies analyzed by two-dimensional affinity electrophoresis. Wang P; Nakamura K Electrophoresis; 1998 Jun; 19(8-9):1506-10. PubMed ID: 9694303 [TBL] [Abstract][Full Text] [Related]
9. Immune response to a hapten of fluorescein isothiocyanate in a single mouse analyzed by two-dimensional affinity electrophoresis. Nakamura K; Mimura Y; Takeo K Electrophoresis; 1993; 14(1-2):81-7. PubMed ID: 8462521 [TBL] [Abstract][Full Text] [Related]
10. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen. Karacay H; Sharkey RM; McBride WJ; Griffiths GL; Qu Z; Chang K; Hansen HJ; Goldenberg DM Bioconjug Chem; 2002; 13(5):1054-70. PubMed ID: 12236788 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of functional T cell priming and contact hypersensitivity responses by treatment with anti-secondary lymphoid chemokine antibody during hapten sensitization. Engeman TM; Gorbachev AV; Gladue RP; Heeger PS; Fairchild RL J Immunol; 2000 May; 164(10):5207-14. PubMed ID: 10799880 [TBL] [Abstract][Full Text] [Related]
12. The donor cell type controls anti-hapten (fluorescein isothiocyanate) primary antibody response to hapten-modified syngeneic cells. Suzuki K; Nakashima I; Takashi M; Nagase F; Kato N; Isobe K; Mizoguchi K; Saito M Immunol Lett; 1982 Oct; 5(4):217-21. PubMed ID: 6816722 [TBL] [Abstract][Full Text] [Related]
13. Characterization of the increased cytotoxicity of gelonin anti-T cell immunoconjugates compared with ricin A chain immunoconjugates. Fishwild DM; Wu HM; Carroll SF; Bernhard SL Clin Exp Immunol; 1994 Jul; 97(1):10-8. PubMed ID: 8033405 [TBL] [Abstract][Full Text] [Related]
14. Essential role of MHC II-independent CD4+ T cells, IL-4 and STAT6 in contact hypersensitivity induced by fluorescein isothiocyanate in the mouse. Takeshita K; Yamasaki T; Akira S; Gantner F; Bacon KB Int Immunol; 2004 May; 16(5):685-95. PubMed ID: 15096484 [TBL] [Abstract][Full Text] [Related]
15. Targeting of indium 111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. Le Doussal JM; Gruaz-Guyon A; Martin M; Gautherot E; Delaage M; Barbet J Cancer Res; 1990 Jun; 50(11):3445-52. PubMed ID: 2334941 [TBL] [Abstract][Full Text] [Related]
16. Folate receptor-targeted immunotherapy: induction of humoral and cellular immunity against hapten-decorated cancer cells. Lu Y; Sega E; Low PS Int J Cancer; 2005 Sep; 116(5):710-9. PubMed ID: 15828051 [TBL] [Abstract][Full Text] [Related]
17. Cell co-operation and hapten--carrier complexes. Snippe H; Kamp E Immunology; 1975 Oct; 29(4):675-85. PubMed ID: 52618 [TBL] [Abstract][Full Text] [Related]
18. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Lu Y; Low PS Cancer Immunol Immunother; 2002 May; 51(3):153-62. PubMed ID: 11941454 [TBL] [Abstract][Full Text] [Related]
19. The thymus origin of the carrier-specific cell in an anti-hapten response in vitro. Trowbridge IS; Anderson HR Eur J Immunol; 1972 Dec; 2(6):565-70. PubMed ID: 4540163 [No Abstract] [Full Text] [Related]
20. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens. Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]